Standard BioTools Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-26.8M | $127.1M | $19.3M | $-34.7M | $-33.5M | $-26.0M | $-34.1M | $-26.9M |
| Depreciation & Amortization | $1.3M | $1.4M | $1.3M | $1.5M | $3.2M | $3.3M | $-393.0K | $3.9M |
| Depreciation | $1.3M | $1.4M | $1.3M | $1.5M | $2.0M | $2.1M | $-1.2M | $1.0M |
| Amortization | $0 | $0 | $0 | $0 | $817.0K | $898.0K | $813.0K | $711.0K |
| Stock-Based Compensation | $4.1M | $8.8M | $5.7M | $8.5M | $6.4M | $9.0M | $7.5M | $5.9M |
| Net Cash from Operating Activities | $-10.3M | $-46.6M | $-1.2M | $-22.2M | $-20.7M | $-30.3M | $-14.1M | $-27.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $344.0K | $570.0K | $476.0K | $886.0K | $1.9M | $5.1M | $3.4M | $2.3M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $14.4M | $191.1M | $-8.0M | $-6.7M | $27.5M | $14.6M | $25.7M | $-30.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Financing Activities | $-138.0K | $-40.0K | $620.0K | $-112.0K | $108.0K | $-46.0K | $-54.5M | $-2.0K |
| Net Change in Cash | $4.3M | $144.6M | $-8.7M | $-29.2M | $7.7M | $-15.3M | $-43.1M | $-59.2M |
| Free Cash Flow | $-10.7M | $-47.2M | $-1.7M | $-23.1M | $-22.6M | $-35.3M | $-17.4M | $-30.1M |